Second Malignant Neoplasms in Childhood Acute Lymphoblastic Leukemia: Primitive Neuroectodermal Tumor of the Chest Wall With Germline p53 Mutation as a Second Malignant Neoplasm

American Journal of Hematology

Volumn 76, Issue 1, 2004, Pages 52-56

  Suarez, Carlos R ^a,b   Bertolone, Salvatore J ^a   Raj, Ashok B ^a   Coventry, Susan ^a  

^a University of Louisville School of Medicine   (United States)

^b PONCE SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Acute lymphoblastic leukemia; Primitive neuroectodermal tumor

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; PROTEIN P53; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CASE REPORT; CHROMOSOME ANALYSIS; DNA SEQUENCE; GENE MUTATION; GERM LINE; HUMAN; HUMAN TISSUE; MALE; NEUROECTODERM TUMOR; PHYSICAL EXAMINATION; PLEURA EFFUSION; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SECOND CANCER; THORAX WALL TUMOR; TUMOR LOCALIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MUTATION; NEOPLASMS, SECOND PRIMARY; NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL; THORACIC WALL; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 2342451330     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20012     Document Type: Article

References (26)

1. Gurney JF, Swenson AR, Bulterys M. Malignant bone tumors. In: Ries LAG, Smith MA, Gurney JG, et al., editors. Cancer incidence and survival among children and adolescents: United States SEER program 1975-1995. National Cancer Institute SEER Program. Pub. No. 99-4649. Bethesda, MD: NCI; 1999. p 99-110.
2. Antillon F, Kaste C, Jenkins J, et al. Primitive neuroectodermal tumor of bone as a second malignant neoplasm in a child previously treated for acute lymphoblastic leukemia. J Ped Hematol Oncol 1997;19:473-476.
3. Neglia JP, Meadows AT, Robinson LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991;325:1330-1336.
4. Bhatia S, Sather HN, Pabustan OB, et al. Low incidence of second neoplasm among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002;99:4257-4264.
5. Löning L, Zimmermann M, Recter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000;95:2770-2775.
6. Meadows AT, D'Angio GJ, Mike V, et al. Patterns of second malignant neoplasms in children. Cancer 1977;40:1903-1911.
7. Tilly H, Bastard C, Chevalier B, et al. Chromosal abnormalities in secondary Ewing's sarcoma. Lancet 1984;2:812.
8. Aparicio J, Segura A, Montalar J, et al. Secondary cancers after Ewing sarcoma and Ewing sarcoma as second malignant neoplasm. Med Pediatr Oncol 1998;30:259-260.
9. Neglia J, Yasui Y, Mertens A, et al. Second primary neoplasms of the central nervous system in survivors of childhood cancer. Proc Am Soc Clin Oncol 2001;20:369a.
10. Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998;16:536-544.
11. Smith LM, Cox RS, Donaldson SS. Second malignancies after Ewing's sarcoma: radiation dose dependency of secondary sarcomas. J Clin Oncol 1996;14:2818-2825.
12. Friedman O, Thompson S, Yasui Y, et al. Genetic risk factors for second malignancy. J Pediatr Hematol Oncol 2000;22:368.
13. Prat B, Geroge SI, Hancock MI, et al. Second malignant neoplasms in survivors of childhood acute lymphocytic leukemia. Pediatr Res 1988;23:345a.
14. Kimball Dalton VM, Gelber RD, Li F, et al. Second malignancies inpatients treated for childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:2848-2853.
15. Nygaard R, Garwicz S, Haldorsen T, et al. Second malignant neoplasms in patients treated for childhood leukemia. Acta Pediatr Scand 1991;80:1220-1228.
16. Haddy TB, Mosher RB, Dindorf PA, et al. Second neoplasms in survivors of childhood cancer. J Pediatr Hematol Oncol 2002;24:A27.
17. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five year survivors of childhood cancer. Childhood Cancer Survivor Study. J Natl Cancer Inst 2001;93:618-629.
18. Walter AW, Hancock ML, Pui CH, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St. Jude Children Research Hospital. J Clin Oncol 1998;16:3761-3767.
19. Wada M, Bartram CR, Nakamura H, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 1993(15);82:3163-3169.
20. Zhu YM, Foroni L, McQuaker IG, et al. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia. Br J Cancer 1999;79:1151-1157.
21. Marks DI, Kurz BW, Link MP, et al. Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J Clin Oncol 1997;15:1158-1162.
22. Diccianni MB, Yu J, Hsiao M, et al. Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood 1994;84:3105-3112.
23. Lam V, McPherson JP, Salmena L, et al. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res 1999;23:871-880.
24. Zhou M, Gu, L, Yeager AM, Findley HW. Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. Leukemia 1998;12:1756-1763.
25. Preudhomme C, Dervite I, Wattel E, et al. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J Clin Oncol 1995 (Apr);13(4):812-820.
26. Fung CY, Fisher DE. p53: from molecular mechanisms to prognosis in cancer. J Clin Oncol 1995(Apr);13(4):808-811.